Patents Assigned to Schering Corporations
  • Aspartyl protease inhibitors
    Patent number: 7560451
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: July 14, 2009
    Assignee: Schering Corporation
    Inventors: Zhaoning Zhu, Andrew W. Stamford, Brian McKittrick
  • Binding compounds specific for cysteine-rich soluble protein C23
    Patent number: 7560533
    Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: July 14, 2009
    Assignee: Schering Corporation
    Inventors: Karin Franz-Bacon, Daniel M. Gorman, Terrill K. McClanahan
  • Imidazopyrazines as protein kinase inhibitors
    Patent number: 7557104
    Abstract: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: July 7, 2009
    Assignee: Schering Corporation
    Inventors: Lianyun Zhao, Panduranga Adulla P. Reddy, Neng-Yang Shih, Kamil Paruch, Timothy J. Guzi, M. Arshad Siddiqui
  • Synthesis of 3-(5-nitrocyclohex-1-enyl) acrylic acid and esters thereof
    Patent number: 7553987
    Abstract: This application discloses provides a process for the introduction of nitro-group functionality into a compound which contains also a site of unsaturation and/or oxygen functionality by direct (one step) oxidation of an oxime functional group mediated by a molybdenum VI/VII peroxo complex, the process comprising: (a) providing a substrate of Formula I containing an oxime functional group; ?wherein R1 and R2 are selected independently from linear, branched or cyclic alkyl and linear, branched or cyclic alkenyl groups, optionally substituted, with the proviso that at least one of R1 or R2 contains a carbon/carbon double bond; and (b) contacting said substrate of Formula I with a molybdenum oxidation complex, thereby oxidizing said oxime functional group to a nitro functional group to yield the structure of Formula III. Where R1 and R2 are as defined above.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: June 30, 2009
    Assignee: Schering Corporation
    Inventors: Tiruvettipuram K. Thiruvengadam, Tao Wang, John S. Chiu, Jing Liao
  • Compounds for the treatment of inflammatory disorders and microbial diseases
    Patent number: 7553864
    Abstract: This invention relates to compounds of the Formulae (I)-(IX): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: June 30, 2009
    Assignee: Schering Corporation
    Inventors: M. Arshad Siddiqui, Umar Faruk Mansoor, Panduranga Adulla P. Reddy, Vincent S. Madison
  • Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
    Patent number: 7550559
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: June 23, 2009
    Assignee: Schering Corporation
    Inventors: Mousumi Sannigrahi, F. George Njoroge, Viyyoor M. Girijavallabhan
  • Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7550467
    Abstract: The present invention discloses compounds of Formula I wherein V, W, Y, Z, R1, R2, R3, R4, d, m, n, p and r are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: June 23, 2009
    Assignee: Schering Corporation
    Inventors: Tao Guo, Huizhong Gu, Douglas Walsh Hobbs
  • ENGINEERED ANTI-IL-23 ANTIBODIES
    Publication number: 20090156788
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 13, 2009
    Publication date: June 18, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • MAMMALIAN GENES; RELATED REAGENTS AND METHODS
    Publication number: 20090155242
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Application
    Filed: September 22, 2008
    Publication date: June 18, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
  • Mammalian Genes: Related Reagents and Methods
    Publication number: 20090156786
    Abstract: Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: December 12, 2008
    Publication date: June 18, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Constance H. Zlot, Gosse Jan Adema, Carl Figdor, Joseph H. Phillips
  • Histamine receptor
    Patent number: 7547523
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: June 16, 2009
    Assignee: Schering Corporation
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick James Monsma, Jr., Kelley L. Morse, Shelby P. Umland, Suke Wang
  • Synthesis of himbacine analogs
    Patent number: 7541471
    Abstract: The present invention relates to an improved process for preparing himbacine analogs. The compounds are useful as thrombin receptor antagonists. The improved process may allow for at least one of easier purification by crystallization, easier scalability, and improved process yield on the desired enantiomer.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: June 2, 2009
    Assignee: Schering Corporation
    Inventors: Tiruvettipuram K Thiruvengadam, Tao Wang, Jing Liao, John S Chiu, David Jieh-Shyh Tsai, Hong-Chang Lee, Wenxue Wu, Xiaoyong Fu
  • Compositions and methods for therapeutic use
    Patent number: 7538093
    Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: May 26, 2009
    Assignees: Schering Corporation, Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Antibodies that bind purified mammalian FLT3 ligands
    Patent number: 7537932
    Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 26, 2009
    Assignees: Schering Corporation, Inserm
    Inventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
  • Compositions and methods for enhancing delivery of therapeutic agents to cells
    Patent number: 7534769
    Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: May 19, 2009
    Assignees: Canji, Inc., Schering Corporation
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Preparation of pharmaceutical salts
    Patent number: 7534884
    Abstract: In one embodiment, the present invention discloses a process to directly prepare an unequal ratio of rotamers of an acid salt from a basic compound, by creative choice of a solvent medium. The process is particularly useful in preparing specific rotamers of pharmaceutically useful salts in desired preponderance.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: May 19, 2009
    Assignee: Schering Corporation
    Inventors: Dinesh Gala, Andrew J. Goodman, Gary Lee, Hongbiao Liao, Martin L. Schwartz, Suhan Tang, David J. S. Tsai, Wenxue Wu
  • Purified mammalian Flt3 ligands; agonists; antagonists
    Patent number: 7534867
    Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 19, 2009
    Assignees: Schering Corporation, Inserm
    Inventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
  • 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-B]pyridin-3-YL]piperidine and methods of use thereof
    Patent number: 7531660
    Abstract: The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: May 12, 2009
    Assignee: Schering Corporation
    Inventors: Manuel de Lera Ruiz, Robert G. Aslanian, Michael Y. Berlin, Kevin D. McCormick, Chander S. Celly
  • Xanthine phosphodiesterase V inhibitors
    Patent number: 7531544
    Abstract: A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: For example, a representative compound of the invention is:
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: May 12, 2009
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Yuguang Wang, Craig D. Boyle, Andrew W. Stamford
  • Kinase inhibitors
    Patent number: 7528132
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: May 5, 2009
    Assignee: Schering Corporation
    Inventors: Tin-Yau Chan, Thierry O. Fischmann, Mark A. McCoy, Brian A. McKittrick, Andrew J. Prongay, Haiyan Pu, Li Wang, Li Xiao